Zhitong Finance App News, Cinda Biotech (01801.HK) announced that daboxin® (ipimumab N01 injection, cytotoxic T lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody (monoclonal antibody), R&D code: IBI310) has been approved for marketing by the China National Drug Administration (NMPA), and is used in conjunction with cindilimab for operatively resectable IIB-III microsatellites highly unstable (MSI-H) or mismatched repair defective (dMMR) colon cancer patients. Daboxin® (ipimumab N01 injection) is the first domestically produced anti-CTLA-4 monoclonal antibody approved in China, and the world's first anti-CTLA-4 monoclonal antibody approved for new adjuvant treatment of colon cancer. Through short-term new adjuvant treatment with cindilizumab, it can significantly improve the rate of complete pathologic remission, benefiting MSI-H/ dMMR colon cancer patients.

Zhitong Finance App News, Cinda Biotech (01801.HK) announced that daboxin® (ipimumab N01 injection, cytotoxic T lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody (monoclonal antibody), R&D code: IBI310) has been approved for marketing by the China National Drug Administration (NMPA), and is used in conjunction with cindilimab for operatively resectable IIB-III microsatellites highly unstable (MSI-H) or mismatched repair defective (dMMR) colon cancer patients. Daboxin® (ipimumab N01 injection) is the first domestically produced anti-CTLA-4 monoclonal antibody approved in China, and the world's first anti-CTLA-4 monoclonal antibody approved for new adjuvant treatment of colon cancer. Through short-term new adjuvant treatment with cindilizumab, it can significantly improve the rate of complete pathologic remission, benefiting MSI-H/ dMMR colon cancer patients.